Surveillance for hepatocellular carcinoma: How can we do better?

American Journal of the Medical Sciences

Volumn 346, Issue 4, 2013, Pages 308-313

  Hassett, Molly ^a   Yopp, Adam C ^a,b   Singal, Amit G ^a,b,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Liver cancer; Quality of care; Screening; Underutilization

Indexed keywords

ALPHA FETOPROTEIN; HEPATITIS C VACCINE;

ABDOMINAL PAIN; ABDOMINAL SWELLING; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CLINICAL FEATURE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; EARLY CANCER; EARLY DIAGNOSIS; EDEMA; HEPATITIS C; HIGH RISK POPULATION; HUMAN; JAUNDICE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; METASTASIS; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROLOGY; SYSTEMATIC REVIEW (TOPIC); ULTRASOUND THERAPY; WEAKNESS; WEIGHT REDUCTION;

EID: 84885019607     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31828318ff     Document Type: Article

References (45)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76 (Pubitemid 46890874)
2. El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817-23
3. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91
4. Tanaka Y, Hanada K, Mizokami M, et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A 2002;99:15584-9 (Pubitemid 35403976)
5. Meissner HI, Smith RA, Rimer BK, et al. Promoting cancer screening: learning from experience. Cancer 2004;101(suppl 5):1107-17 (Pubitemid 39100409)
6. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998;27:273-8 (Pubitemid 28041564)
7. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73 (Pubitemid 43042691)
8. Velazquez RF, Rodriguez M, Navascues CA, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003;37:520-7 (Pubitemid 36258772)
9. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2010;53:1-35
10. Jepsen P, Ott P, Andersen PK, et al. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study. Ann Intern Med 2012;156:841-7
11. Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(5 suppl 1): S35-50 (Pubitemid 39423368)
12. Singal AG, Waljee A, Mukherjee A, et al. Machine learning algorithms outperform conventional regression models in identifying risk factors for hepatocellular carcinoma in patients with cirrhosis. Gastroenterology 2012;142(5 suppl 1):S984
13. Chalasani N, Said A, Ness R, et al. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey. Am J Gastroenterol 1999;94:2224-9 (Pubitemid 29374558)
14. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009;30:37-47
15. Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010;138:493-502
16. Singal AG, Conjeevaram HS, Volk ML, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev 2012;21:793-9
17. Finberg HJ Whither (wither?) the ultrasound specialist? J Ultrasound Med 2004 23 1543-7
18. Olsen AH, Bihrmann K, Jensen MB, et al. Breast density and outcome of mammography screening: a cohort study. Br J Cancer 2009;100:1205-8
19. Marrero JA. Screening tests for hepatocellular carcinoma. Clin Liver Dis 2005;9:235-51, v. i.
20. Colli A, FraquelliM, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006;101:513-23 (Pubitemid 43340927)
21. Trevisani F, D'Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001;34:570-5 (Pubitemid 32328514)
22. Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 2003;139:46-50 (Pubitemid 38124619)
23. Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma AFP, DCP, and AFP-L3 in hepatocellular carcinoma. Gastroenterology 2009;137:110-8
24. Sheu JC, Sung JL, Chen DS, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985;89:259-66
25. Trinchet JC, Cendrine C, Bourcier V, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3-and 6-month periodicities. Hepatology 2011;54:1987-97
26. Yang B, Zhang B, Xu Y, et al. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol 1997;123:357-60 (Pubitemid 27286510)
27. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417-22
28. Trevisani F, De NS, Rapaccini G, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002;97:734-44 (Pubitemid 34245906)
29. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996;101:422-34 (Pubitemid 26392861)
30. Arguedas MR, Chen VK, Eloubeidi MA, et al. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003;98:679-90 (Pubitemid 36348544)
31. Lin OS, Keeffe EB, Sanders GD, et al. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004;19:1159-72 (Pubitemid 38746259)
32. Leykum LK, El-Serag HB, Cornell J, et al. Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. Clin Gastroenterol Hepatol 2007;5: 508-12 (Pubitemid 46575370)
33. Davila JA, Henderson L, Kramer JR, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 2011;154:85-93
34. Davila JA, Morgan RO, Richardson PA, et al. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010;52:132-41
35. Palmer L, Kappelman M, Porter C, et al. Screening for hepatocellular carcinoma in a medicaid cirrhotic population: opportunities for improvement. Gastroenterology 2010;138(suppl 1):S-796
36. Singal AG, Yopp A, Skinner CS, et al. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med 2012;27:861-7
37. Klabunde CN, Brown M, Ballard-Barbash R, et al. Cancer Screening-United States, 2010. MMWR Morb Mortal Wkly Rep. January 27, 2012 2012
38. Singal AG, Tiro J, Gupta S. Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening. Clin Gastroenterol Hepatol 2013 (epub ahead of print) doi 10.1016/j.cgh. 2012.11.010
39. Taplin SH, Rodgers AB. Toward improving the quality of cancer care: addressing the interfaces of primary and oncology-related subspecialty care. J Natl Cancer Inst Monogr 2010;2010:3-10
40. Zapka JG, Taplin SH, Solberg LI, et al. A framework for improving the quality of cancer care: the case of breast and cervical cancer screening. Cancer Epidemiol Biomarkers Prev 2003;12:4-13 (Pubitemid 36110151)
41. Holmes-Rovner M, Valade D, Orlowski C, et al. Implementing shared decision-making in routine practice: barriers and opportunities. Health Expect 2000;3:182-91 (Pubitemid 30646742)
42. Stravitz RT, Heuman DM, Chand N, et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med 2008;121:119-26 (Pubitemid 351199465)
43. Singal AG, Yopp A, Gupta S, et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila) 2012;5:1124-30
44. Singal A, Volk M, Rakoski M, et al. Patient involvement is correlated with higher HCC surveillance in patients with cirrhosis. J Clin Gastroenterol 2011;45:727-32
45. Singal AG, Nehra M, Adams-Huet B, et al. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroentol. 2013 (epub ahead of print) doi 10.1038/ajg.2012.449.